In good news for people who suffer from chronic migraines, researchers have identified a medication that can prevent the severe headaches before they start. An antibody therapy against a key inflammatory molecule involved in migraines reduces the number of headaches that chronic migraine patients experience per month in a phase III trial. By blocking this peptide, doctors hope to break the cycle of increasing inflammation and increased pain sensitivity that contributes to migraine headaches. The first group received quarterly treatments, the second group received one treatment per month and the third group received placebo injections. "We saw some patients with 100 per cent reduction in migraine, others with 75 per cent reduction," said Silberstein.

Source: dna December 03, 2017 10:15 UTC